TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis
Authors:
- 9 June 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 344 (3) , 765-771
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Electrotransfer of human IL‐1Ra into skeletal muscles reduces the incidence of murine collagen‐induced arthritisThe Journal of Gene Medicine, 2004
- Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion proteinGene Therapy, 2003
- Inflammatory Mediators and the Failing HeartCirculation Research, 2002
- Cytokine Gene Therapy for Myocarditis by In Vivo ElectroporationHuman Gene Therapy, 2001
- Adeno-Associated Virus Production of Soluble Tumor Necrosis Factor Receptor Neutralizes Tumor Necrosis Factor α and Reduces ArthritisHuman Gene Therapy, 2000
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- Increased circulating cytokines in patients with myocarditis and cardiomyopathy.Heart, 1994
- Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.Journal of Experimental Medicine, 1994
- TUMOR NECROSIS FACTOR: A Pleiotropic Cytokine and Therapuetic TargetAnnual Review of Medicine, 1994
- Tumour necrosis factors α and β inhibit virus replication and synergize with interferonsNature, 1986